Physician profile

Jack J Berger

Rheumatology · Purchase, NY

NPI 1770568719

$1,569.24

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$337.74

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Novartis Pharmaceuticals Corporation $365.65 2019-2023
Abbvie INC. $249.53 2020-2022
Pfizer INC. $247.49 2019
Amgen INC. $130.98 2022
Ucb, INC. $125.00 2019
Astrazeneca Pharmaceuticals LP $124.52 2021
Mallinckrodt Hospital Products INC. $122.91 2023 Acthar
Ani Pharmaceuticals, INC. $115.54 2024 Purified Cortrophin Gel
Lilly USA, LLC $87.62 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Jack J Berger

$1,569.24

in general payments reported 2019-2025

Years
2019-2024
Top company
Novartis Pharmaceuticals Corporation

https://glasscript.com/doctor/306807/jack-j-berger

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.